Needham & Company Reiterates a 'Buy' on Alnylam Pharma (ALNY); Phase 2b Trial Misses, But Shares Still Undervalued

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. MRNA
2. TGT
3. MRK
4. PANW
5. KEYS
6. KLAR
7. LOW
8. UBER
9. SPY
10. PGR

Go back to Needham & Company Reiterates a 'Buy' on Alnylam Pharma (ALNY); Phase 2b Trial Misses, But Shares Still Undervalued
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Delayed: 242.61 --0 (-0%)
Previous Close $242.61    52 Week High $109.10 
Open $242.61    52 Week Low $31.38 
Day High $242.61    P/E N/A 
Day Low $242.61    EPS $-1.45 
Volume 203